866-997-4948(US-Canada Toll Free)

Global Transdermal Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts

Published By :

Current Partnering

Published Date : Apr 2016

Category :

Drug Delivery

No. of Pages : 157 Pages

Topical Drug Delivery Partnering 2010-2015 report provides understanding and access to the topical drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

  • Trends in topical drug delivery partnering deals
  • Top topical drug delivery deals by value
  • Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Topical Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Topical Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Topical Drug Delivery partnering deals.

The report presents financial deal term values for Topical Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Topical Drug Delivery partnering field; both the leading deal values and most active Topical Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 200 online deal records of actual Topical Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Topical Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Topical Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Topical Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Topical Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Topical Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Topical Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Topical Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Topical Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Topical Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Topical Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Topical Drug Delivery technologies and products.

Report scope

Global Topical Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Topical Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Topical Drug Delivery Partnering Terms and Agreements includes:

  • Trends in Topical Drug Delivery dealmaking in the biopharma industry since 2010
  • Analysis of Topical Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Topical Drug Delivery deals
  • Access to Topical Drug Delivery contract documents
  • Leading Topical Drug Delivery deals by value since 2010
  • Most active Topical Drug Delivery dealmakers since 2010

In Global Topical Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Topical Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 200 Topical Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Topical Drug Delivery Partnering 2010-2016 report provides the reader with the following key benefits:

  • In-depth understanding of Topical Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Topical Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Topical Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Topical Drug Delivery dealmakers since 2010
  • Insight into terms included in a Topical Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Transdermal Drug Delivery dealmaking
2.1. Introduction
2.2. Transdermal Drug Delivery partnering over the years
2.3. Most active Transdermal Drug Delivery dealmakers
2.4. Transdermal Drug Delivery partnering by deal type
2.5. Transdermal Drug Delivery partnering by therapy area
2.6. Deal terms for Transdermal Drug Delivery partnering
2.6.1 Transdermal Drug Delivery partnering headline values
2.6.2 Transdermal Drug Delivery deal upfront payments7
2.6.3 Transdermal Drug Delivery deal milestone payments
2.6.4 Transdermal Drug Delivery royalty rates

Chapter 3 Leading Transdermal Drug Delivery deals
3.1. Introduction
3.2. Top Transdermal Drug Delivery deals by value

Chapter 4 Most active Transdermal Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Transdermal Drug Delivery dealmakers
4.3. Most active Transdermal Drug Delivery partnering company profiles

Chapter 5 Transdermal Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Transdermal Drug Delivery contracts dealmaking directory

Chapter 6 Transdermal Drug Delivery dealmaking by technology type

Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 Transdermal Drug Delivery deals by company A-Z
Appendix 2 Transdermal Drug Delivery deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 Transdermal Drug Delivery deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 Transdermal Drug Delivery deals by therapy area
Appendix 5 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Table

NA

List of Chart

Figure 1: Transdermal Drug Delivery partnering since 2010
Figure 2: Active Transdermal Drug Delivery dealmaking activity 2010 to 2016
Figure 3: Transdermal Drug Delivery partnering by deal type since 2010
Figure 4: Transdermal Drug Delivery partnering by disease type since 2010
Figure 5: Transdermal Drug Delivery deals with a headline value
Figure 6: Transdermal Drug Delivery deals with an upfront value
Figure 7: Transdermal Drug Delivery deals with a milestone value
Figure 8: Transdermal Drug Delivery deals with a royalty rate value
Figure 9: Top Transdermal Drug Delivery deals by value since 2010
Figure 10: Most active Transdermal Drug Delivery dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *